Bronchitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Bronchitis - Pipeline Review, H2 2016

Bronchitis - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Bronchitis - Pipeline Review, H2 2016
Published Sep 28, 2016
59 pages — Published Sep 28, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Bronchitis - Pipeline Review, H2 2016, provides an overview of the Bronchitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchitis
- The report reviews pipeline therapeutics for Bronchitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bronchitis therapeutics and enlists all their major and minor projects
- The report assesses Bronchitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bronchitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bronchitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing stra

  
Source:
Document ID
GMDHC8502IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Bronchitis Overview71
Therapeutics Development81
  Pipeline Products for Bronchitis Overview81
Bronchitis Therapeutics under Development by Companies91
Bronchitis Pipeline Products Glance103
  Late Stage Products101
  Clinical Stage Products111
  Early Stage Products121
Bronchitis Products under Development by Companies131
Bronchitis Companies Involved in Therapeutics Development149
  AstraZeneca Plc141
  DBV Technologies S.A.151
  F. Hoffmann-La Roche Ltd.161
  Hyundai Pharmaceutical Co., Ltd.171
  Invion Limited181
  Kyorin Pharmaceutical Co., Ltd.191
  Mucosis B.V.201
  Orbis Biosciences Inc211
  Recipharm AB221
Bronchitis Therapeutics Assessment239
  Assessment by Monotherapy Products231
  Assessment by Target242
  Assessment by Mechanism of Action262
  Assessment by Route of Administration282
  Assessment by Molecule Type302
Drug Profiles3218
  alteplase Drug Profile322
  AZD-9668 Drug Profile341
  erdosteine Drug Profile352
  HOB-051 Drug Profile371
  KRPAM-1977X Drug Profile382
  nadolol Drug Profile404
  nitric oxide Drug Profile442
  prednisone Drug Profile461
  respiratory syncytial virus vaccine Drug Profile471
  SynGEM Drug Profile482
Bronchitis Dormant Projects502
Bronchitis Discontinued Products521
Bronchitis Product Development Milestones535
  Featured News &Press Releases531
    Nov 10, 2015: Recipharm secures 25 million contract for Erdosteine API with Daewoong Pharmaceutical531
    Nov 10, 2015: Recipharm secures 25 million contract for Erdosteine API with Daewoong Pharmaceutical531
    Oct 07, 2015: EVP R&D Dr Mitchell Glass discusses with BRR media data from the Phase 2 clinical trial of INV102 (nadolol) in Smoking Cessation541
    Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets541
    Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings551
    Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants551
    Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL561
    Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine562
Appendix582
  Methodology581
  Coverage581
  Secondary Research581
  Primary Research581
  Expert Panel Validation581
  Contact Us581
  Disclaimer591

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Bronchitis - Pipeline Review, H2 2016" Sep 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bronchitis-Pipeline-Review-H2-2016-2088-16615>
  
APA:
Global Markets Direct - Market Research. (2016). Bronchitis - Pipeline Review, H2 2016 Sep 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Bronchitis-Pipeline-Review-H2-2016-2088-16615>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.